

## 1 Evidence of a Sjögren's disease-like phenotype following COVID-19

2  
3 Yiran Shen<sup>1\*</sup>, Alexandria Voigt<sup>1\*</sup>, Laura Goranova<sup>1</sup>, Mehdi Abed<sup>2</sup>, David E. Kleiner<sup>3</sup>, Jose O.  
4 Maldonado<sup>2,4</sup>, Margaret Beach<sup>2</sup>, Eileen Pelayo<sup>2</sup>, John A. Chiorini<sup>4</sup>, William F. Craft<sup>5</sup>, David A.  
5 Ostrov<sup>6</sup>, Vijay Ramiya<sup>7</sup>, Sukesh Sukumaran<sup>8</sup>, Apichai Tuanyok<sup>1</sup>, Blake M. Warner<sup>2#</sup>, and Cuong  
6 Q. Nguyen<sup>1,9,10#</sup>

7  
8 <sup>1</sup>Department of Infectious Diseases and Immunology, College of Veterinary Medicine, University  
9 of Florida, Gainesville, Florida, USA; <sup>2</sup>Salivary Disorder Unit, National Institute of Dental and  
10 Craniofacial Research, NIH, Bethesda, Maryland; <sup>3</sup>Laboratory of Pathology, Center for Cancer  
11 Research, National Cancer Institute, NIH, Bethesda, Maryland; <sup>4</sup>AAV Biology Section, National  
12 Institute of Dental and Craniofacial Research, NIH, Bethesda, Maryland, USA; <sup>5</sup>Department of  
13 Comparative, Diagnostic, and Population Medicine, College of Veterinary Medicine, University  
14 of Florida, Gainesville, Florida, USA; <sup>6</sup>Department of Pathology, Immunology & Laboratory  
15 Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA; <sup>7</sup>LifeSouth  
16 Community Blood Centers, Gainesville FL, <sup>8</sup>Valley Children's Hospital, Madera, California;  
17 <sup>9</sup>Department of Oral Biology, College of Dentistry; <sup>10</sup>Center of Orphaned Autoimmune Diseases,  
18 University of Florida, Gainesville, Florida, USA.

19 \*Authors contributed equally to the study

20 #Co-correspondence authors.

21  
22 Address correspondence:

23 Cuong Q. Nguyen, PhD  
24 Department of Infectious Diseases and Immunology  
25 PO Box 110880, College of Veterinary Medicine  
26 University of Florida, Gainesville, Florida 32611-0880. USA

27 Telephone: 352-294-4180, Fax: 352-392-9704

28

29 Blake M. Warner, DDS, PhD, MPH

30 Salivary Disorders Unit

31 Building 10 Room 1A01

32 10 Center Drive

33 National Institutes of Health

34 Bethesda, MD 20895

35

36 **Key Messages:**

37 What is already known about this subject?

- 38 • SAR-CoV-2 has a tropism for the salivary glands. However, whether the virus can  
39 induce clinical phenotypes of Sjögren's disease is unknown.

40 What does this study add?

- 41 • Mice infected with SAR-CoV-2 showed loss of secretory function, elevated  
42 autoantibodies, and lymphocyte infiltration in glands.
- 43 • COVID-19 patients showed an increase in autoantibodies. Monoclonal antibodies  
44 produced in recovered patients can block ACE2/spike interaction and recognize nuclear  
45 antigens.
- 46 • Minor salivary gland biopsies of some convalescent subjects showed focal lymphocytic  
47 infiltrates with focus scores.

48 How might this impact on clinical practice or future developments?

- 49 • Our data provide strong evidence for the role of SARS-CoV-2 in inducing Sjögren's  
50 disease-like phenotypes.
- 51 • Our work has implications for how patients will be diagnosed and treated effectively.

52

53 **Abstract**

54 **Objectives:**

55 Sjögren's Disease (SjD) is a chronic and systemic autoimmune disease characterized by  
56 lymphocytic infiltration and the development of dry eyes and dry mouth resulting from the  
57 secretory dysfunction of the exocrine glands. SARS-CoV-2 may trigger the development or  
58 progression of autoimmune diseases, as evidenced by increased autoantibodies in patients and  
59 the presentation of cardinal symptoms of SjD. The objective of the study was to determine  
60 whether SARS-CoV-2 induces the signature clinical symptoms of SjD.

61 **Methods:**

62 The ACE2-transgenic mice were infected with SARS-CoV-2. SJD profiling was conducted.  
63 COVID-19 patients' sera were examined for autoantibodies. Clinical evaluations of convalescent  
64 COVID-19 subjects, including minor salivary gland (MSG) biopsies, were collected. Lastly,  
65 monoclonal antibodies generated from single B cells of patients were interrogated for  
66 ACE2/spike inhibition and nuclear antigens.

67 **Results:**

68 Mice infected with the virus showed a decreased saliva flow rate, elevated antinuclear  
69 antibodies (ANAs) with anti-SSB/La, and lymphocyte infiltration in the lacrimal and salivary  
70 glands. Sera of COVID-19 patients showed an increase in ANA, anti-SSA/Ro52, and anti-  
71 SSB/La. The male patients showed elevated levels of anti-SSA/Ro52 compared to female  
72 patients, and female patients had more diverse ANA patterns. Minor salivary gland biopsies of  
73 convalescent COVID-19 subjects showed focal lymphocytic infiltrates in four of six subjects, and  
74 2 of 6 subjects had focus scores >2. Lastly, we found monoclonal antibodies produced in  
75 recovered patients can both block ACE2/spike interaction and recognize nuclear antigens.

76 **Conclusion:**

77 Overall, our study shows a direct association between SARS-CoV-2 and SjD. Hallmark features  
78 of SjD salivary glands were histologically indistinguishable from convalescent COVID-19

79 subjects. The results potentially implicate that SARS-CoV-2 could be an environmental trigger  
80 for SJD.

81

82

83 **Key Words:**

84

85 Sjögren's Disease (SjD), Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),

86 Coronavirus disease 2019 (COVID-19), Autoimmune disease, Autoantibodies.

87

## 88 Introduction

89 Sjögren's Disease (SjD) is an autoimmune disease that is generally categorized by sicca  
90 symptoms in the mouth and eyes, the presence of autoantibodies, and lymphocytic infiltration  
91 into the salivary gland[1,2]. It is estimated that approximately 4 million Americans are affected,  
92 making SjD the second most common autoimmune disease after rheumatoid arthritis[3–5]. SjD  
93 has the most skewed sex distribution known, with a 9:1 ratio of women to men[6]. SjD is most  
94 closely associated with symptoms of dryness, particularly of the mouth and eyes; however, a  
95 wide variety of extraglandular manifestations have been reported involving virtually any organ or  
96 tissue[4,7]. The extraglandular manifestations of SjD have been subdivided into visceral  
97 (gastrointestinal tract, lungs, heart, central and peripheral nervous system) and non-visceral  
98 (muscles, joints, skin) involvement, indicating the wide variety of tissues that may be involved in  
99 the disease. While both men and women at any age can be affected by SjD, it is most  
100 commonly diagnosed in women in the fourth or fifth decade of life[7,8]. The pathological  
101 framework of SjD pathogenesis remains elusive, however studies have suggested the primary  
102 drivers are genetic susceptibility, hormonal factors, and environmental triggers.

103 In December 2019, a novel coronavirus, severe acute respiratory syndrome-coronavirus-  
104 2 (SARS-CoV-2), emerged in Wuhan, Hubei Province, China, initiating a breakout of atypical  
105 acute respiratory disease, termed coronavirus disease 2019 (COVID-19). SARS-CoV-2 is a  
106 *betacoronavirus* in the family of *Coronaviridae*; the virus contains four structural proteins: S  
107 (spike), E (envelope), M (membrane), and N (nucleocapsid), sixteen non-structural proteins  
108 (nsp1–16) and eleven accessory proteins, which support viral essential physiological function  
109 and evasion from the host immune system[9]. As of May 1<sup>st</sup>, 2022, approximately one million  
110 U.S. residents have died from COVID-19[10], with more than 80 million total cases. Recent  
111 studies have identified the association between SARS-CoV-2 infection and autoimmune  
112 response. A recent literature review[11] (n= 1176 articles and 90 case reports) revealed that the  
113 primary rheumatic diseases associated with COVID-19 patients were vasculitis, arthritis,

114 idiopathic inflammatory myopathies, and systemic lupus erythematosus. Several studies have  
115 found an association between antinuclear antibodies (ANAs) (35.6%) and COVID-19 infection,  
116 where the leading reactive antigens include SSA/Ro (25%), rheumatoid factor (19%), lupus  
117 anticoagulant (11%), and type I interferons (IFN-I) (10%)[12–14]. In 6 independent case studies,  
118 COVID-19 patients were diagnosed with systemic sclerosis[15], adult-onset Still's disease[16],  
119 sarcoidosis, and systemic lupus erythematosus (SLE) with 4/6 patients acutely manifesting  
120 during COVID-19. An elevated level of anti-SSA/Ro52 in COVID-19 patients was linked to  
121 pneumonia severity and poor prognosis[17]. The underlying mechanism for the production of  
122 autoantibodies in COVID-19 patients is unknown, however, it poses a significant challenge for  
123 post-COVID-19 symptoms or post-acute sequelae of SARS-CoV-2 (PASC).

124 There are reports and cases of COVID-19 patients experiencing ocular and oral  
125 symptoms. Keratoconjunctivitis was observed in a few patients during a specific phase of the  
126 disease[18]. One study has shown that xerostomia was observed in 29% of the patient  
127 cohort[19] while another showed an increase of 30% in reporting xerostomia during  
128 hospitalization[20]. While these early studies had small sample sizes, the results appeared to  
129 indicate an association between COVID-19 and oral and ocular manifestations, primary  
130 symptoms of SjD. Increased rates of xerostomia in this patient cohort may be explained by  
131 tropism of SARS-CoV-2 for the salivary glands, resulting in host immune response and immune-  
132 mediated injury[21]. Furthermore, growing evidence of autoantibody production in COVID-19  
133 patients raises a critical question as to whether SARS-CoV-2 infection is a risk factor for primary  
134 SjD. Therefore, the goal of this study was to determine the autoimmune response triggered by  
135 SARS-CoV-2 infection. The results indicate that infection with SARS-CoV-2 recapitulated an  
136 SjD-like phenotype in transgenic mice. Additionally, we show by using human sera paired by  
137 sex, age, and race that not only do they contain general autoantibodies but those associated  
138 with SjD, namely anti-SSA/Ro52 and anti-SSB/La.

139



## 140 **Methods**

### 141 **Human samples**

142 SARS-CoV-2 positive and healthy control (HC) sera were obtained from the CTSI  
143 Biorepository at University of Florida in compliance with IRBs 202001475 and 2020000781. The  
144 presence of SARS-CoV-2 was confirmed by RT-PCR for admittance into the CTSI Biorepository  
145 Bank. Peripheral blood mononuclear cells (PBMC) from five post-convalescent COVID-19  
146 donors were obtained from LifeSouth Community Blood Centers (Gainesville FL). The healthy  
147 volunteer donors had recovered from COVID-19 and were positive for SARS-CoV2 antibodies  
148 at the time of blood donation. The donors had no prior clinically diagnosed autoimmune  
149 diseases. Handling of the samples was performed in a certified BSL2+ with Institutional  
150 Biosafety Committee approved protocols.

151 *NIDCR Subjects and Protocols:* Subjects were consented to National Institutes of Health  
152 (NIH) Central Institutional Review Board (IRB)-approved protocols (15-D-0051: *Characterization*  
153 *of Salivary Gland Disorders* [PI-Warner]; 20-D-0094: *Transmissibility and Viral Load of SARS-*  
154 *CoV-2 in Oral Secretions* [PI-Warner]) and evaluated at either the NIH SARS-CoV-2 Field  
155 Testing Facility (20-D-0094) or the NIH Clinical Center. NIH IRB Protocol: 15-D-0051  
156 (NCT02327884), is a cross-sectional screening protocol to evaluate subjects with a variety of  
157 disorders affecting the salivary complex and also, healthy subjects (i.e., healthy volunteers  
158 [HV]). All enrolled subjects are evaluated comprehensively including: oral, sialometric,  
159 ophthalmologic, and rheumatologic evaluations; salivary gland ultrasonography, bloodwork  
160 including rheumatologic investigations, and minor salivary gland (MSG) biopsies. NIH IRB  
161 Protocol: 20-D-0094 (NCT04348240) was a short-term longitudinal study aimed at examining  
162 the potential transmissibility and viral load of SARS-CoV-2 in saliva when compared with nasal  
163 and nasopharyngeal secretions, and for testing the effectiveness of masks to reduce speaking-  
164 related transmission[21]. The general results of this study are reported in Huang, et al.,

165 (2021)[21]. After identifying SARS-CoV-2 in saliva, the protocol was amended to allow MSG  
166 biopsy in acute and convalescent COVID-19 subjects[21].

167 Research and clinical records post-initiation of the global COVID-19 pandemic were  
168 reviewed systematically by a rheumatology Physicians Assistant (MB). Subjects were included  
169 in the histopathological analysis if they had recovered from COVID-19, had convalescent MSG  
170 biopsies, and were enrolled on NIH IRB Protocols: 15-D-0051 or 20-D-0094. Subjects were  
171 excluded if they were evaluated as a patient for the workup for SjD or non-SjD sicca symptoms.  
172 Comprehensive investigations as described above were completed on subjects enrolled on our  
173 15-D-0051 protocol, but due to constraints of the NIH SARS-CoV-2 Field Testing Facility, these  
174 parameters were not able to be collected on all 20-D-0094 subjects. Clinical laboratory studies  
175 at NIH include standard bloodwork, assays for antinuclear antibodies (ANA), antibodies to  
176 extractable nuclear antigens (e.g., anti-SSA/SSB autoantibodies), and antibodies to pathogens  
177 to assess vaccination and exposure history purposes (e.g., anti-spike, anti-nucleocapsid). In  
178 one subject (subject 2), serial MSG biopsies were collected; the first was taken 5 days after the  
179 first COVID-19 symptoms (reported previously as COV49[21]) and the second was taken 6  
180 months later[21].

181 MSG biopsies were interpreted by a board-certified anatomic pathologist (DEK) for  
182 diagnostic purposes and the histopathology was systematically reviewed by a board-certified  
183 oral and maxillofacial pathologist (BMW) as previously described (PMID: 30996010). Salivary  
184 gland inflammation and fibrosis were graded according to Greenspan et al. [PMID: 4589360]  
185 and Tarpley et al. [PMID: 4586901]. For MSG with Greenspan grade 3 or 4 sialadenitis, a focus  
186 score was calculated according to Daniels et al. [PMID: 1055974]. Hematoxylin and eosin  
187 [H&E], CD20, CD3, CD4, CD8) was conducted by the Anatomic Pathology Laboratory of the  
188 National Cancer Institute. Slides were scanned at x40 with a NanoZoomer S360 slide scanner  
189 (Hammamatsu Photonics, Hammamatsu-city, Japan), and digital photomicrographs at x5  
190 resolution were captured using NDP.view2 software (Hammamatsu Photonics).

191

192

## 193 **Results**

### 194 **SARS-CoV-2 triggered the decrease in the salivary secretory function.**

195         SjD patients experience xerostomia, primarily as a result of the diminished secretory  
196 function of the salivary glands. In the spontaneous animal models of SjD, the secretory  
197 dysfunction occurs between 15-20 weeks of age. Here, we sought to determine if SARS-CoV-2  
198 can compromise saliva secretion by the glands. The homozygous K18-hACE2 mice were  
199 intranasally inoculated with 860 PFU of SARS-CoV-2 WA1/2020 inoculum drop-by-drop into  
200 both nostrils until fully inhaled. Saliva were collected on day 21 prior to euthanization. As  
201 shown, the infected mice showed a significant loss of salivary flow rates compared to the  
202 uninfected mice (infected:  $6.64 \pm 1.075$  vs uninfected:  $13.12 \pm 0.532$  ul/gr) (**Figure 1A**). The loss  
203 of saliva was equivalent to approximately a 50% reduction in function (**Figure 1B**). The infected  
204 mice showed a decrease in body weight when compared to the uninfected mice; however, the  
205 decrease was not statistically significant (**Figure 1C**). The results suggest that SARS-CoV-2  
206 infection has a negative effect on the secretory function of the salivary glands.

207

### 208 **SARS-CoV-2 induced the production of autoantibodies.**

209         Seropositivity for ANA and anti-SSA/Ro is one of the major classifying criteria for SjD.  
210 Here, we sought to determine if SARS-CoV-2 infection was able to induce autoantibody  
211 production. As presented in **Figure 2A**, 70% of infected mice were positive and 30% were  
212 negative for ANA using HEP2 cell staining. Whereas, in the uninfected mice, 70% were  
213 negative, and 30% were positive for ANA. Furthermore, we examined the SjD-specific  
214 autoantibodies. As indicated in **Figure 2B**, anti-SSB/La levels were highly elevated in the  
215 infected group in comparison to the control group. There was a slight, though statistically  
216 insignificant, increase in anti-SSA/Ro52 levels in the infected group. There was no change in

217 anti-SSA/Ro60 levels between the two groups. The results suggest that SARS-CoV-2 infection  
218 in mice promotes the development of ANA and autoantibodies signature to SjD.

219

### 220 **SARS-CoV-2 caused inflammation in the lacrimal and salivary glands of mice.**

221 The principal targeted tissues for SjD are the lacrimal and salivary glands. The  
222 inflammatory lesions are composed of a multitude of immune cell types, notably B cells, T cells,  
223 and macrophages. The lacrimal glands of infected mice had multifocal apoptosis/necrosis of low  
224 to moderate numbers of acinar epithelial cells characterized by cells with condensed,  
225 hypereosinophilic cytoplasm and pyknotic nuclei with karyorrhexis. The apoptosis/necrosis  
226 resulted in variable collapse and loss of acini. The interlobular duct epithelium was unaffected.  
227 The salivary glands of infected mice showed a lymphoid nodule in the interstitium, a sign of  
228 lymphocyte infiltration which was not present in control mice (**Figure 3A**). Elevated number of  
229 apoptotic cells were found in both glands of infected mice (**Figure 3B**). Macrophages were  
230 more consistent in the salivary glands of infected mice with a smaller frequency of T or B cells.  
231 Whereas, macrophages in the lacrimal glands of infected mice were elevated drastically and  
232 consistently in the infected mice in comparison to the salivary gland. Similarly, B and T cells  
233 were detected at higher frequencies in the lacrimal than in the salivary glands (**Figure 3B**).  
234 Lymphocytic foci were detected in both the lacrimal and salivary glands of the infected mice, but  
235 not those of the control mice. Only a single infected mouse developed a focus score (FS) in the  
236 salivary glands, so deviation from the control group is insignificant ( $\chi^2=.27$ ,  $p= 0.10247$ ).  
237 However, FS were detected in the lacrimal glands of 5 infected mice ( $\chi^2=13$ ,  $p= 0.00031$ ) (**Table**  
238 **S1**). Additionally, lymphocytic infiltration of B and/or T cells which does not qualify as a focus  
239 was examined. This is an indicator of localized inflammation in the salivary ( $\chi^2=11$ ,  $p= 0.00091$ )  
240 and lacrimal glands ( $\chi^2=24$ ,  $p= 0.00001$ ). Overall, SARS-CoV-2 induced inflammation with  
241 multifocal apoptosis/necrosis with more severity in the lacrimal than salivary glands.

242

243 **COVID-19 is associated with higher autoantibody levels in a sex-specific manner.**

244 As described above, mice infected with SARS-CoV-2 developed ANA and elevated anti-  
245 SSB/La. Here, we sought to determine if these findings were also observed in human patients.  
246 As presented in **Figure 4A**, the COVID-19 patients exhibited higher frequencies of positive ANA  
247 at different sera titers compared to healthy controls. Notably, 60% patients showed positive  
248 ANA with none for healthy controls at 1:160 titer. 30% patients still exhibited positive ANA at  
249 1:320 titer. Further analysis of the staining patterns revealed that among the positive ANA for  
250 patients, 40% were homogeneous, 15% were speckled, and 5% were centromeric (**Figure 4B**).  
251 To further determine if the COVID-19 patients presented with SjD signature autoantibodies,  
252 patient sera were examined for reactivity against SSA/Ro52, SSA/Ro60, and SSB/La. As  
253 presented in **Figure 4C**, anti-SSA/Ro52 and anti-SSB/La were significantly elevated in COVID-  
254 19 patients in comparison to healthy controls. Anti-SSB/Ro60 levels remained similar between  
255 the two groups.

256 SjD has a strong predilection for females; therefore, we sought to determine whether  
257 COVID-19 patients exhibited an element of sexual dimorphism in the autoantibody response.  
258 Interestingly, when examining the ANA staining it was discovered that the female COVID-19  
259 patients had a significantly higher percentage of positive ANA at various titers compared to  
260 either the male COVID-19 patients or either sex of control patients (**Figure S1A**). Additionally,  
261 the female COVID-19 patients were shown to present a more diverse ANA pattern, with 30%  
262 speckled, 40% homogenous, and 10% centromeric at 1:160 titer, whereas the male patient  
263 showed 10% speckled and 30% homogenous pattern at the same titer. The female patient still  
264 exhibited 20% speckled with males showed 10% speckled at 1:320 titer and homogenous  
265 pattern remained the same for both sexes. positive staining for all other groups only contained  
266 a homogenous pattern (**Figure S1B**). To further determined if male and female COVID-19  
267 patients exhibited different levels of SjD signature autoantibodies, we analyzed the samples  
268 based on sex. As presented in **Figure S1C**, female and male COVID-19 patients showed

269 significantly higher levels of anti-SSA/Ro52 in comparison to their respective counterparts.  
270 Interestingly, male COVID-19 patients showed elevated levels of anti-SSA/Ro52 above female  
271 COVID-19 patients ( $p=0.0029$ ). There was no statistically significant difference between male  
272 and female COVID-19 patients with anti-SSA/Ro60 or anti-SSB/La. The results indicated that  
273 female patients manifested more diverse patterns of ANA, however male patients exhibited  
274 higher levels of anti-SSA/Ro52 than female patients.

275

276 **Monoclonal antibodies produced by COVID-19 patients are reactive against nuclear**  
277 **antigens.**

278 It is remarkable to observe the cross-reactivity of COVID-19 patients' sera against self-  
279 antigens as demonstrated. To further evaluate the B cell response of COVID-19 patients, we  
280 produced and selected nine monoclonal antibodies (mAbs) from convalescent COVID-19  
281 patients by isolating CD20<sup>+</sup> memory B cells reactive against both the RBD and S1 of SARS-  
282 CoV-2, and examined their response to self-antigens. As presented in **Figure S2A**, the mAbs  
283 exhibited various degrees of inhibition against SARS-CoV-2 RBD, in which mAbs A10 and B5  
284 showed the highest inhibitory activity at different dilutions. To determine if they react against  
285 nuclear antigens, we tested them against HEp2 cells. As described in **Figure S2B**, seven of the  
286 nine S1/RBD-reactive mAbs produced a strong homogenous staining pattern with 100% at 1:40  
287 and 1:80 titers and lowered to 90% at 1:160 and 1:320 titers. Overall, the results demonstrate  
288 that mAbs against the virus produced in recovered COVID-19 patients are cross-reactive and  
289 capable of recognizing nuclear antigens.

290

291 **Convalescent COVID-19 subjects demonstrate inflammation of the salivary glands and**  
292 **clinical signs and symptoms of Sjögren's Disease.**

293 Six generally-healthy, relatively young (Range: 19-42y; Mean: 31y) subjects who had  
294 recovered from COVID-19, had convalescent MSG biopsies were identified for the study. These

295 subjects were free from evidence of pre-existing autoimmune disease or major medical  
296 conditions. Subjects 1-3 were enrolled on NIH IRB Protocol: 20-D-0094 and had convalescent  
297 MSG biopsies 6-13 months after recovery from COVID-19 (Table 1). In addition, Subject 2 also  
298 received an initial biopsy during acute COVID-19 (Table 1, Figure 5). These subjects recovered  
299 from COVID-19 without continued post-acute COVID-19 symptoms as primary clinical concerns.  
300 Subjects 4-6 were enrolled on an NIH IRB Protocol: 15-D-0051 as healthy volunteers (HV) and  
301 did not present with clinical complaints of Sjogren's Disease or post-acute COVID-19 syndrome  
302 (Table 1). Their COVID-19 status was determined from subject interviews and serological  
303 studies. In subjects with known COVID-19, their clinical course was generally mild; three of the  
304 subjects reported lung involvement with shortness of breath without hospitalization and a single  
305 subject reported significant gastrointestinal involvement ('mild-to-moderate COVID-19'). A single  
306 subject, Subject 5 was unaware of their post-COVID-19 status and was considered  
307 'asymptomatic'. Evidence of infection included clinical reports of infection in five of six subjects,  
308 clinical nasopharyngeal swab PCR for SARS-CoV-2 N1 and N2 genes in four subjects (S1-3,6);  
309 anti-nucleocapsid antibodies were positive in all six subjects (*data not shown*). No subjects were  
310 positive for anti-nuclear antibodies (ANA) or anti-SSA/Ro antibodies. A single subject was low-  
311 titre positive for anti-SSB/La antibodies. Three of the six subjects reported dry mouth during  
312 acute COVID-19 which was sustained temporarily after recovery (up to 3 weeks); a single  
313 subject had objective evidence of dry mouth (Subject 2) during acute COVID-19. Interestingly,  
314 this subject did not produce saliva from the submandibular glands for ~3 of the 4 weeks of  
315 weekly follow up after infection. Dry eye assessments could not be completed in the NIH  
316 COVID-19 Testing Facility for three subjects, two of the three subjects who presented through  
317 the NIH Dental Clinic had objective evidence of dry eye disease (**Table 1**) but did not have  
318 clinical complaints of dry eyes.

319 Overall, seven MSG biopsies were collected from 6 subjects - a single subject had serial  
320 biopsies. One biopsy occurred during acute COVID-19 5 days after symptom debut, and the

321 second 6 months after recovery. Generally, biopsies exhibited mild chronic sialadenitis (**Table**  
322 **1**). However, 5 of the 7 biopsies (from four of the six subjects) had multiple foci (>50  
323 lymphocytes) of inflammation (e.g., focal lymphocytic sialadenitis, FLS; **Table 1**, **Figure 5**,  
324 **Figure S3**). Most foci were small, although several glands exhibited multiple medium-sized and  
325 coalescing foci. Mild fibrosis and atrophy of the glands were seen in three subjects (Subject 1-  
326 3). It is noteworthy that Subject 2's follow-up biopsy exhibited evidence of sustained immune  
327 insult as evidenced by an increased focus score (FS:1 → FS:2) and the elaboration of fibrosis  
328 and atrophy of the glands (**Figure 5**). Histopathological evidence of injury included ductal injury  
329 and mucous inspissation, immune infiltration of the acini with injury, perivascular infiltrates, and  
330 granuloma. In some subjects, the histopathological features in four of six subjects (five biopsies)  
331 are reminiscent of the range of histopathological features found in the MSG of SjD patients.

332 To understand the composition of the immune infiltrates, clinical immunophenotyping  
333 was performed on four biopsies from three subjects. The infiltrates generally composed of  
334 varying proportions of T cells and B cells with small foci being predominantly T cells and larger  
335 foci exhibiting a shifted balance towards B cell predominance. CD8 T cells were found both  
336 scattered throughout the gland and also in the inflammatory foci (**Figure 6**, **Table 2**). These  
337 immunohistochemical studies are highly similar to the inflammatory infiltrates found  
338 characteristically in SjD. In the single subject (S2) with follow up MSG, the amount of  
339 inflammation and the shift to B cell predominance can be appreciated in the areas of FLS at 6  
340 months.

341



## 342 Discussion

343 Increasing evidence has supported the associations between viral/bacterial infections  
344 and autoimmune diseases. An early study demonstrated that murine cytomegalovirus induced  
345 an SjD-like disease in C57Bl/6-lpr/lpr mice with sialadenitis, severe salivary gland inflammation,  
346 and production of anti-SSA/Ro and anti-SSB/La[28]. Recent studies suggested that the virus  
347 has a tropism for the SG, including SARS-CoV-2[21,29]. Here, we sought to determine if SARS-  
348 CoV-2 infection could also trigger SjD-like phenotypes in a murine model. The results indicate  
349 that SARS-CoV-2 infection recapitulates several signature disease phenotypes, specifically,  
350 diminished salivary flow rates, salivary and lacrimal gland inflammatory lesions, and elevated  
351 autoantibodies. Similar findings were also observed in COVID-19 patients, in which, significantly  
352 elevated levels of anti-SSA/Ro52 and anti-SSB/La were seen. Additionally, female patients  
353 manifested more diverse patterns of ANA, and male patients exhibited higher levels of anti-  
354 SSA/Ro52 than female patients. In summary, the data suggest that SARS-CoV-2 infection  
355 triggered a SjD-like disease in a murine model as well as in human patients.

356 SARS-CoV-2 primarily uses ACE2 as a receptor[30,31], which is broadly expressed by  
357 endothelial and epithelial cells, including those of the aerodigestive tract and the salivary  
358 glands[21,32–34]. It has now been shown that salivary glands can robustly support infection and  
359 replication of SARS-CoV-2, and that saliva is potentially infectious and transmissible[21]. Intra-  
360 individual spread of SARS-CoV-2 initiates from the epithelial cells of the upper respiratory tract  
361 (e.g., acinar and ductal cells of the salivary glands) by active replication and egress of offspring  
362 viruses subsequently infecting ACE2-expressing cells in downstream organs, including the  
363 heart, kidneys, gastrointestinal tract, and vasculature[21,35,36]. The hACE2 transgenic model  
364 expressed high levels of hACE2 in the lacrimal glands and a lesser amount in the salivary  
365 glands. The tissue and cellular tropism of SARS-CoV-2 were not noticeably different between  
366 the two glands at the study endpoint. The more severe lacrimal gland inflammation and cell  
367 death could be attributed to the higher expression of hACE2, which allows for active viral

368 infection and replication, however, the endpoint timeline was not able to capture these temporal  
369 infectious changes (**Figures S4 and S5**). ACE2 is expressed in squamous epithelial cells of the  
370 dorsal tongue, gingiva, and buccal tissue, and TMPRSS2 is expressed in taste bud cells and  
371 submandibular glands. SARS-CoV-2 was detected in SGs with higher levels in the minor SGs.  
372 In addition, saliva is a natural reservoir for viruses as one of the major fluids for viral detection.  
373 Therefore, it is not surprising that SARS-CoV-2 was found in the SGs and facilitated the  
374 inflammatory response.

375         The severity of COVID-19 is mediated by unregulated inflammation. During the later  
376 stage of the disease, immune-mediated damage leads to a progressive increase in  
377 inflammation. And patients with life-threatening pneumonia had neutralizing autoantibodies  
378 against IFN- $\omega$  and IFN- $\alpha$ [14]. As demonstrated, mice infected with SARS-CoV-2 developed  
379 higher levels of ANA and anti-SSB/La levels. Similarly, patients developed elevated levels of  
380 ANA, specifically anti-SSA/Ro52 and anti-SSB/La. In a study analyzing the sera and plasma  
381 from 64 COVID-19 patients, approximately 25% of patients exhibited an autoantibody response  
382 on average 12.3 days post-diagnosis and the reactivity was primarily to nuclear antigens,  
383 including RNP (n=8), SSA, SSB, dsDNA, chromatin, or centromere[37] Chang et al. showed that  
384 autoantibodies are present in approximately 15% of healthy controls and 50% of COVID-19  
385 patients against commonly recognized antigens in an array of autoimmune disorders, including  
386 SSA/Ro52[38]. However, Burbelo, et al., 2022 demonstrated that a considerable fraction of the  
387 autoantibody positivity in severe COVID-19 subjects may be related to receipt of intravenous  
388 immunoglobulins (IVIG)[39]. Thus, these results suggest the need for longitudinally sampled  
389 and controlled serosurveillance need to be performed. A metaanalysis revealed that the  
390 development of primary rheumatic diseases associated with COVID-19 patients were vasculitis,  
391 arthritis, idiopathic inflammatory myopathies, and systemic lupus erythematosus; overall, the  
392 association between ANAs (35.6%) and COVID-19 infection was 35.6% and the reactive  
393 antigens were found at the following rates: SSA (25%), rheumatoid factor (19%), lupus

394 anticoagulant (11%), and IFN-I (10%)[11]. Autoantibody responses in COVID-19 patients can be  
395 influenced by sex, with men exhibiting an autoantibody response after an infection defined as at  
396 least mildly symptomatic, whereas women were prone to produce this response following an  
397 asymptomatic infection; thus autoantibody profiles are highly variable between the sexes and  
398 dependent on the disease severity[40]. It is unknown how SARS-CoV-2 infection could induce a  
399 plethora of autoantibodies, specifically autoimmune-specific antibodies. One hypothesis is that  
400 tropism of SARS-CoV-2 to vulnerable cells triggers a robust immune response that damages  
401 virally-infected cells leading to the presentation of anti-viral proteins-viral particle-antibody  
402 immune complexes to antigen presenting cells in the interstitium. A study showed that  
403 heptapeptide sharing exists between SARS-CoV-2 spike glycoprotein and human proteins, an  
404 indication of the molecular mimicry mechanism[41]. However, the spike protein does not share  
405 any homology with SjD-specific autoantigens. Therefore, it remains to be determined the  
406 underlying mechanism of autoantibody response triggered by SARS-CoV-2.

407 We, and others, have confirmed that salivary glands are exquisitely supportive of  
408 infection and replication of SARS-CoV-2, and saliva is an ideal secretion for inter and intra-  
409 individual spread of de novo virus[21,42]. Because of the long-hypothesized connection  
410 between viral infection and the initiation of autoimmune diseases, we examined available clinical  
411 data and minor salivary gland biopsies from convalescent COVID-19 subjects with mild-to-  
412 moderate infections. While no patients satisfied strict 2016 ACR/EULAR classification criteria,  
413 focal lymphocytic sialadenitis or clinical signs and symptoms of SjD were found in most of the  
414 available subjects[43]. In select patients, the histopathological features of inflammation in the  
415 salivary glands are indistinguishable from SjD and in the proper clinical context would be  
416 supportive of the diagnosis.

417 The most prevalent and persistent oral symptoms associated with COVID-19 include  
418 taste dysfunction, in addition to that, dry mouth (xerostomia) is often overlooked in COVID-19  
419 patients and was identified as another highly prevalent (43%) oral manifestation of COVID-

420 19[44]. A review of 12 studies, including patients diagnosed with SARS-CoV-2 infection from  
421 different countries with reported oral symptoms associated COVID-19 infection showed that  
422 xerostomia occurs in the early stages of COVID-19 with a prevalence ranging from 20% to  
423 61.9%, and can persist for at least 8 months after recovery[45]. The percentage is higher in  
424 patients with mild symptoms, as a study in Israel showed 61.9% of 97 confirmed non-  
425 hospitalized patients reported xerostomia[46]. This is consistent with our data showing a  
426 markedly diminished salivary secretion after SARS-CoV-2 infection in mice. The precise etiology  
427 of gland dysfunction requires further investigation. As demonstrated, the influx of inflammatory  
428 cells in the glands, concomitantly with the rapid increase of acinar cell apoptosis/necrosis, may  
429 contribute to the diminished gland function. We did not measure tear secretion, mainly to avoid  
430 further physical stress on the mice as a result of the drug side effect and handling.

431 In summary, our study underpins the pathogenic role of SARS-CoV-2 in SjD. SARS-  
432 CoV-2 induced gland inflammation leading to the loss of saliva in mice. It triggered the  
433 production of SjD-specific autoantibodies in mice and human patients. This study raises the  
434 prospect of managing SjD in long COVID-19. Further studies are needed to examine the  
435 pathoetiology of SARS-CoV-2 in SjD.

436  
437  
438  
439

440 **Competing interests**

441 All authors have no competing interests.

442

443

444 **Data availability statement**

445           Data are available upon reasonable request

446

447 **Ethics statement**

448 **Patient consent for publication**

449 Not required

450 **Ethics approval**

451 Subjects were consented to National Institutes of Health (NIH) Central Institutional  
452 Review Board (IRB)-approved protocols (15-D-0051: *Characterization of Salivary Gland*  
453 *Disorders* [PI-Warner]; 20-D-0094: *Transmissibility and Viral Load of SARS-CoV-2 in Oral*  
454 *Secretions* [PI-Warner]). Convalescent samples were collected under the University of Florida  
455 approved protocol (IRB202000781). Participants gave informed consent to participate in the  
456 study before taking part.

457

458

459

460 **Acknowledgments**

461           This research was funded by the National Institutes of Health (NIH), National Institute of  
462 Dental and Craniofacial Research (NIDCR), Division of Extramural Research (DE028544, PI-  
463 Nguyen; DE028544-02S1, PI-Nguyen), and the NIH/NIDCR Division of Intramural Research  
464 (Z01-DE000704, PI-Warner; Z01-DE00695, PI-Chiorini). We give our special thanks to the  
465 members of the NIDCR Sjögren's Disease Clinical Research Team for their coordination of  
466 patients and collection of research data and tissues.

467

468

469

470

471

472



473 **Figure legends**

474 **Figure 1: Decrease in saliva secretion by salivary glands by SARS-CoV-2. A.** Saliva flows  
475 were collected as described in the materials and methods section. The data shown represent  
476 the saliva flow rate (ul/gram). The mice were randomly selected for saliva collection at the  
477 endpoint (control/uninfected n=8 and infected n=8). To minimize the exposure of working in  
478 BSL-3 mouse colony, the smaller number of mice was chosen for saliva collection. **B.** The  
479 mean percentage loss of saliva flow rates (SFR) in comparison to the control mice, which was  
480 set at 100. **C.** The weight of the mice in grams (control n=11, infected n=8) Data were  
481 presented as mean  $\pm$  SEM. One-tailed Mann-Whitney t-tests were performed where \*\*\* p<  
482 0.001, ns: not significant.

483

484 **Figure 2: Autoantibody profile of mouse sera. A)** ANA profile was determined using HEp2  
485 cells. A Chi-squared test was performed on the control (n=10, 5 females, 5 males) and SARS-  
486 CoV-2 infected samples (n=13, 6 males, 7 females), with a value of 32, p <0.00001. Sera were  
487 diluted as described and positive signals were detected at 1:40-1:320 titers. **B)** Anti-SSB/La,  
488 anti-SSA/Ro52, and anti-SSA/Ro60 were determined using ELISA. Welch's t-test was  
489 performed to determine the significance of these results, where \*\*\*p= 0.0003, ns: not significant.

490

491 **Figure 3: Histological examination of lymphocytes in the salivary and lacrimal glands. A)**  
492 H&E staining of the salivary and lacrimal glands of the control and SARS-CoV-2 infected mice.  
493 Inlets with red arrows showed the apoptotic/necrotic acinar cell bodies (control, n=5 females:  
494 infected, n=26, 13 males, 13 females). **B)** Elevated number of apoptotic cells in the salivary and  
495 lacrimal glands of the infected mice. **C)** Increase in the frequency of macrophage in salivary  
496 and lacrimal glands of the infected mice. Enumeration of immune cells using  
497 immunofluorescent staining. Identification of infiltrating cells in the salivary glands and lacrimal  
498 glands, where immunofluorescent staining of CD3<sup>+</sup> T cells, B220<sup>+</sup> B cells and CD68<sup>+</sup>

499 macrophages are displayed in yellow, red, and green, respectively, with blue DAPI nuclei  
500 staining. One-tailed Mann-Whitney t-tests were performed where \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$  \*\*\*\*  $p <$   
501  $0.0001$ . Con: Control, SG: salivary glands, LG: lacrimal glands.

502  
503 **Figure 4: Autoantibody induction in COVID-19 human sera. A)** ANA profile was determined  
504 using HEp2 slides at various sera titers. **B)** A breakdown by specific ANA staining pattern is  
505 presented. **C)** Anti-SSB/La, anti-SSA/Ro52, and anti-SSA/Ro60 were determined using ELISA  
506 Welch's t-test was performed to determine the significance of these results, where \*\* $p = 0.0015$   
507 and \* $p = 0.0415$ .

508  
509 **Figures 5: Representative minor salivary glands H&E photomicrographs of health (HV),**  
510 **Sjogren's Disease (SjD), and two representative subjects recovered from COVID-19.**  
511 Convalescent glands exhibit a range of inflammation severity ranging from normal to mild-to-  
512 moderate sialadenitis with focal lymphocytic sialadenitis reminiscent of inflammation found in  
513 SjD. The histopathological findings from three patients (P2 & P5) exhibit inflammation consistent  
514 with findings observed in SjD salivary glands (e.g., focal lymphocytic sialadenitis with focus  
515 scores  $>1.0$ ). However, P1, P3, and P6 exhibited FLS but did not reach the threshold of  $>1.0$   
516 focus per  $4\text{mm}^2$  of tissue.

517  
518 **Figures 6: Representative immunophenotyping studies examining CD3, CD4, CD8, and**  
519 **CD20 on a minor salivary gland biopsy during infection (D5 post first symptom; FS: 1)**  
520 **and post (6 Months) COVID-19 infection (P2).** Immunophenotyping demonstrates diffuse  
521 mild-to-moderate chronic sialadenitis with focal lymphocytic sialadenitis. The infiltrate is  
522 strikingly similar to infiltrates found in SjD with a predominant T cell and B cell in the ducts and  
523 acini associated with inflammation.

524



## 526 Bibliography

- 527 1 Lee BH, Tudares MA, Nguyen CQ. Sjögren's syndrome: an old tale with a new twist. *Arch*  
528 *Immunol Ther Exp (Warsz)* 2009;**57**:57–66. doi:10.1007/s00005-009-0002-4
- 529 2 Nguyen CQ, Peck AB. Unraveling the pathophysiology of Sjogren syndrome-associated dry  
530 eye disease. *Ocul Surf* 2009;**7**:11–27. doi:10.1016/S1542-0124(12)70289-6
- 531 3 Helmick CG, Felson DT, Lawrence RC, *et al.* Estimates of the prevalence of arthritis and  
532 other rheumatic conditions in the United States. Part I. *Arthritis Rheum* 2008;**58**:15–25.  
533 doi:10.1002/art.23177
- 534 4 Vivino FB, Bunya VY, Massaro-Giordano G, *et al.* Sjogren's syndrome: An update on  
535 disease pathogenesis, clinical manifestations and treatment. *Clin Immunol* 2019;**203**:81–  
536 121. doi:10.1016/j.clim.2019.04.009
- 537 5 Thomas E, Hay EM, Hajeer A, *et al.* Sjögren's syndrome: a community-based study of  
538 prevalence and impact. *Br J Rheumatol* 1998;**37**:1069–1076.  
539 doi:10.1093/rheumatology/37.10.1069
- 540 6 Qin B, Wang J, Yang Z, *et al.* Epidemiology of primary Sjögren's syndrome: a systematic  
541 review and meta-analysis. *Ann Rheum Dis* 2015;**74**:1983–1989. doi:10.1136/annrheumdis-  
542 2014-205375
- 543 7 Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjögren  
544 syndrome. *Arch Intern Med* 2004;**164**:1275–1284. doi:10.1001/archinte.164.12.1275
- 545 8 Bayetto K, Logan RM. Sjögren's syndrome: a review of aetiology, pathogenesis, diagnosis  
546 and management. *Aust Dent J* 2010;**55 Suppl 1**:39–47. doi:10.1111/j.1834-  
547 7819.2010.01197.x
- 548 9 Wang M-Y, Zhao R, Gao L-J, *et al.* SARS-CoV-2: Structure, Biology, and Structure-Based  
549 Therapeutics Development. *Front Cell Infect Microbiol* 2020;**10**:587269.  
550 doi:10.3389/fcimb.2020.587269
- 551 10 Mortality Analyses - Johns Hopkins Coronavirus Resource Center.  
552 <https://coronavirus.jhu.edu/data/mortality> (accessed 12 Jun2020).
- 553 11 Gracia-Ramos AE, Martin-Nares E, Hernández-Molina G. New Onset of Autoimmune  
554 Diseases Following COVID-19 Diagnosis. *Cells* 2021;**10**. doi:10.3390/cells10123592
- 555 12 Gazzaruso C, Carlo Stella N, Mariani G, *et al.* High prevalence of antinuclear antibodies  
556 and lupus anticoagulant in patients hospitalized for SARS-CoV2 pneumonia. *Clin*  
557 *Rheumatol* 2020;**39**:2095–2097. doi:10.1007/s10067-020-05180-7
- 558 13 Zhou Y, Han T, Chen J, *et al.* Clinical and Autoimmune Characteristics of Severe and  
559 Critical Cases of COVID-19. *Clin Transl Sci* 2020;**13**:1077–1086. doi:10.1111/cts.12805
- 560 14 Bastard P, Rosen LB, Zhang Q, *et al.* Autoantibodies against type I IFNs in patients with  
561 life-threatening COVID-19. *Science* 2020;**370**. doi:10.1126/science.abd4585
- 562 15 Fineschi S. Case Report: Systemic Sclerosis After Covid-19 Infection. *Front Immunol*  
563 2021;**12**:686699. doi:10.3389/fimmu.2021.686699
- 564 16 Bamidis AD, Koehler P, di Cristanziano V, *et al.* First manifestation of adult-onset Still's  
565 disease after COVID-19. *Lancet Rheumatol* 2021;**3**:e319–e321. doi:10.1016/S2665-  
566 9913(21)00072-2
- 567 17 Fujii H, Tsuji T, Yuba T, *et al.* High levels of anti-SSA/Ro antibodies in COVID-19 patients  
568 with severe respiratory failure: a case-based review□: High levels of anti-SSA/Ro  
569 antibodies in COVID-19. *Clin Rheumatol* 2020;**39**:3171–3175. doi:10.1007/s10067-020-  
570 05359-y
- 571 18 Mao L, Jin H, Wang M, *et al.* Neurologic manifestations of hospitalized patients with  
572 coronavirus disease 2019 in Wuhan, China. *JAMA Neurol* Published Online First: 10 April  
573 2020. doi:10.1001/jamaneurol.2020.1127
- 574 19 Luo Y, Wu J, Lu J, *et al.* Investigation of COVID-19-related symptoms based on factor  
575 analysis. *Ann Palliat Med* 2020;**9**:1851–1858. doi:10.21037/apm-20-1113

- 576 20 Sinjari B, D'Ardes D, Santilli M, *et al.* SARS-CoV-2 and Oral Manifestation: An  
577 Observational, Human Study. *J Clin Med* 2020;**9**. doi:10.3390/jcm9103218
- 578 21 Huang N, Pérez P, Kato T, *et al.* SARS-CoV-2 infection of the oral cavity and saliva. *Nat*  
579 *Med* 2021;**27**:892–903. doi:10.1038/s41591-021-01296-8
- 580 22 Mendoza EJ, Manguiat K, Wood H, *et al.* Two Detailed Plaque Assay Protocols for the  
581 Quantification of Infectious SARS-CoV-2. *Curr Protoc Microbiol* 2020;**57**:ecpmc105.  
582 doi:10.1002/cpmc.105
- 583 23 Witas R, Rasmussen A, Scofield RH, *et al.* Defective efferocytosis in a murine model of  
584 sjögren's syndrome is mediated by dysfunctional mer tyrosine kinase receptor. *Int J Mol Sci*  
585 2021;**22**. doi:10.3390/ijms22189711
- 586 24 Esfandiary L, Gupta N, Voigt A, *et al.* Single-cell antibody nanowells: a novel technology in  
587 detecting anti-SSA/Ro60- and anti-SSB/La autoantibody-producing cells in peripheral blood  
588 of rheumatic disease patients. *Arthritis Res Ther* 2016;**18**:107. doi:10.1186/s13075-016-  
589 1010-5
- 590 25 Rodda LB, Netland J, Shehata L, *et al.* Functional SARS-CoV-2-Specific Immune Memory  
591 Persists after Mild COVID-19. *Cell* 2021;**184**:169–183.e17. doi:10.1016/j.cell.2020.11.029
- 592 26 Tiller T, Busse CE, Wardemann H. Cloning and expression of murine Ig genes from single  
593 B cells. *J Immunol Methods* 2009;**350**:183–193. doi:10.1016/j.jim.2009.08.009
- 594 27 Gupta S, Li D, Ostrov DA, *et al.* Blocking IAg7 class II major histocompatibility complex by  
595 drug-like small molecules alleviated Sjögren's syndrome in NOD mice. *Life Sci*  
596 2022;**288**:120182. doi:10.1016/j.lfs.2021.120182
- 597 28 Fleck M, Kern ER, Zhou T, *et al.* Murine cytomegalovirus induces a Sjögren's syndrome-  
598 like disease in C57Bl/6-lpr/lpr mice. *Arthritis Rheum* 1998;**41**:2175–2184.  
599 doi:10.1002/1529-0131(199812)41:12<2175::AID-ART12>3.0.CO;2-I
- 600 29 Maldonado JO, Beach ME, Wang Y, *et al.* HCV infection alters salivary gland histology and  
601 saliva composition. *J Dent Res* 2022;**101**:534–541. doi:10.1177/00220345211049395
- 602 30 Zhou P, Yang X-L, Wang X-G, *et al.* A pneumonia outbreak associated with a new  
603 coronavirus of probable bat origin. *Nature* 2020;**579**:270–273. doi:10.1038/s41586-020-  
604 2012-7
- 605 31 Lu G, Hu Y, Wang Q, *et al.* Molecular basis of binding between novel human coronavirus  
606 MERS-CoV and its receptor CD26. *Nature* 2013;**500**:227–231. doi:10.1038/nature12328
- 607 32 Lu R, Zhao X, Li J, *et al.* Genomic characterisation and epidemiology of 2019 novel  
608 coronavirus: implications for virus origins and receptor binding. *Lancet* 2020;**395**:565–574.  
609 doi:10.1016/S0140-6736(20)30251-8
- 610 33 Li W, Moore MJ, Vasilieva N, *et al.* Angiotensin-converting enzyme 2 is a functional  
611 receptor for the SARS coronavirus. *Nature* 2003;**426**:450–454. doi:10.1038/nature02145
- 612 34 Hoffmann M, Kleine-Weber H, Schroeder S, *et al.* SARS-CoV-2 Cell Entry Depends on  
613 ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell*  
614 2020;**181**:271–280.e8. doi:10.1016/j.cell.2020.02.052
- 615 35 Wölfel R, Corman VM, Guggemos W, *et al.* Virological assessment of hospitalized patients  
616 with COVID-2019. *Nature* 2020;**581**:465–469. doi:10.1038/s41586-020-2196-x
- 617 36 Cao W, Li T. COVID-19: towards understanding of pathogenesis. *Cell Res* 2020;**30**:367–  
618 369. doi:10.1038/s41422-020-0327-4
- 619 37 Lerma LA, Chaudhary A, Bryan A, *et al.* Prevalence of autoantibody responses in acute  
620 coronavirus disease 2019 (COVID-19). *J Transl Autoimmun* 2020;**3**:100073.  
621 doi:10.1016/j.jtauto.2020.100073
- 622 38 Chang SE, Feng A, Meng W, *et al.* New-onset IgG autoantibodies in hospitalized patients  
623 with COVID-19. *Nat Commun* 2021;**12**:5417. doi:10.1038/s41467-021-25509-3
- 624 39 Burbelo PD, Castagnoli R, Shimizu C, *et al.* Autoantibodies Against Proteins Previously  
625 Associated With Autoimmunity in Adult and Pediatric Patients With COVID-19 and Children  
626 With MIS-C. *Front Immunol* 2022;**13**:841126. doi:10.3389/fimmu.2022.841126

- 627 40 Liu Y, Ebinger JE, Mostafa R, *et al.* Paradoxical sex-specific patterns of autoantibody  
628 response to SARS-CoV-2 infection. *J Transl Med* 2021;**19**:524. doi:10.1186/s12967-021-  
629 03184-8
- 630 41 Kanduc D, Shoenfeld Y. Molecular mimicry between SARS-CoV-2 spike glycoprotein and  
631 mammalian proteomes: implications for the vaccine. *Immunol Res* 2020;**68**:310–313.  
632 doi:10.1007/s12026-020-09152-6
- 633 42 Matuck BF, Dolhnikoff M, Duarte-Neto AN, *et al.* Salivary glands are a target for SARS-  
634 CoV-2: a source for saliva contamination. *J Pathol* 2021;**254**:239–243.  
635 doi:10.1002/path.5679
- 636 43 Shiboski CH, Shiboski SC, Seror R, *et al.* 2016 American College of  
637 Rheumatology/European League Against Rheumatism classification criteria for primary  
638 Sjögren’s syndrome: A consensus and data-driven methodology involving three  
639 international patient cohorts. *Ann Rheum Dis* 2017;**76**:9–16. doi:10.1136/annrheumdis-  
640 2016-210571
- 641 44 Amorim Dos Santos J, Normando AGC, Carvalho da Silva RL, *et al.* Oral Manifestations in  
642 Patients with COVID-19: A 6-Month Update. *J Dent Res* 2021;**100**:1321–1329.  
643 doi:10.1177/00220345211029637
- 644 45 Tsuchiya H. Characterization and Pathogenic Speculation of Xerostomia Associated with  
645 COVID-19: A Narrative Review. *Dentistry Journal* 2021;**9**. doi:10.3390/dj9110130
- 646 46 Biadsee A, Dagan O, Ormianer Z, *et al.* Eight-month follow-up of olfactory and gustatory  
647 dysfunctions in recovered COVID-19 patients. *Am J Otolaryngol* 2021;**42**:103065.  
648 doi:10.1016/j.amjoto.2021.103065  
649  
650

651

**Table 1. Clinical and histopathological features of convalescent COVID-19 subjects and comparators.**

Sub.	Sex	Patient type	Histopathological Diagnosis	Focus Score <sup>a</sup>	Fibrosis/ Atrophy	Other Features	Oral Symptoms	Oral Signs	Ocular symptoms	Ocular Signs	COVID-19 Severity	Biopsy Post COVID-19
1 <sup>d</sup>	F	Conv.	FLS with Mild Chronic Sialadenitis	0 <sup>b</sup>	N		N	N/A	N	NA	Mild	8
2 <sup>d</sup>	F	Conv.	FLS with Mild Chronic Sialadenitis	1	Y	Duct injury and dilatation	Y	Y	N/A	N/A	Mild	0 <sup>c</sup>
			FLS with Mild-to- Moderate Chronic Sialadenitis	2	Y	GC	Y	N	N/A	N/A		6
3 <sup>d</sup>	M	Conv.	FLS with Mild Chronic Sialadenitis	0 <sup>b</sup>	Y	Inflam. infiltrating acini	Y	N/A	N/A	N/A	Mild-to-Moderate	13
4 <sup>e</sup>	F	HV	Mild Chronic Sialadenitis	0	N		N	N	N	Y	Mild-to-Moderate	21
5 <sup>e</sup>	M	HV	FLS with Mild-to-Moderate Chronic Sialadenitis	2	N	GC, granuloma	N	N	N	N	Asymp.	UNK
6 <sup>e</sup>	M	HV	FLS with Mild Chronic Sialadenitis	0 <sup>b</sup>	N	Perivascular infiltrates	Y	N	N	Y	Mild-to-Moderate	7
SjD <sup>e</sup>	F	SjD	FLS with Mild-to- Moderate Chronic Sialadenitis	2	Y		Y	Y	Y	Y		
CTL <sup>e</sup>	F	HV	Normal Histology	0	N		N	N	N	N		

<sup>a</sup>The focus score (FS) is the number of inflammatory infiltrates of at least 50 cells present in 4 mm<sup>2</sup> of salivary gland area.

<sup>b</sup>The subjects has focal lymphocytic sialadenitis (FLS) but with less than 1 per 4 mm<sup>2</sup> of tissue. P2 has 8 foci per 37 mm<sup>2</sup> of tissue (FS: 0.9) and P6 has 5 foci per 25 mm<sup>2</sup> (FS: 0.8), and thus are borderline. Subject 3 has 4 foci per ~47 mm<sup>2</sup> (FS: 0.3).

<sup>c</sup>The patient had a biopsy 5 days after first symptom of COVID-19. Patient 2 clinical D5 case was reported in Huang, Perez, et al., *Nature Med.* 2021 (ref).

<sup>d</sup>The subjects were enrolled on 20-D-0094 and biopsied as convalescent subjects (Subjects 1-3).

<sup>e</sup>The subjects were enrolled on 15-D-0051 as either affected subjects ("SjD") or healthy volunteers (HV) (Subjects 4-6 and Ex: HV).




Age range of subjects and comparators was 19-42 years.



Abbreviations: F, female; M, male; Conv., convalescent; N, no; Y, yes; FLS, focal lymphocytic sialadenitis; GC, germinal center; UNK, unknown; SjD, Sjögren's Disease; HV, healthy volunteer; CTL, control gland from healthy volunteer.













***Table 2. Immunophenotyping of convalescent COVID-19 subjects salivary glands.***




<b>Subject</b>	<b>CD20</b>	<b>CD3</b>	<b>CD4</b>	<b>CD8</b>	<b>CD4:CD8</b>
1	+	++	++	+	CD4>CD8
2-1	+	++	++	+	CD4>CD8
2-2	++	++	++	++	CD4>CD8
3	+	+	+	+	CD4>CD8














**A.****B.**

**A.****Con-SG****Infected-SG****Con-LG****Infected-LG****B.****C.****CD3/CD68****B220/CD68****CD68**






**P2 - Day 3**




**5X**


**CD20**




**CD3**




**CD4**



**CD8**




**P2 - 6 Months**




**5X**


**CD20**



**CD3**



**CD4**



**CD8**

